The data reinforces setmelanotide's efficacy across multiple rare obesity indications, supporting revenue growth trajectory. Monitor upcoming regulatory milestones for bivamelagon and PWS expansion. The stock has limited near-term catalyst beyond these data; long-term holders should watch for label expansion updates and quarterly sales figures.
Price Chart
Executive Summary
Rhythm Pharmaceuticals presented positive clinical and real-world data at ENDO 2026 for setmelanotide and bivamelagon across multiple rare obesity indications (acquired hypothalamic obesity, BBS, PWS). The data showed sustained weight loss, hunger reduction, and improved healthcare utilization, reinforcing the commercial thesis for its MC4R agonist platform. The stock market reaction is likely muted as the data is incremental and consistent with prior disclosures, but the breadth of positive readouts across indications supports the long-term pipeline value.
Key Facts
- Setmelanotide achieved -18.9% mean BMI reduction at 2.5 years in acquired HO patients (n=11).
- Oral bivamelagon showed -8.7% to -16.6% BMI reduction at 1 year across dose cohorts (n=26).
- 71.1% of pediatric and 71.4% of adult acquired HO patients achieved ≥1 weight category improvement with setmelanotide vs 13.6% and 6.7% on placebo.
- Real-world BBS data (n=286): 62% of adults achieved ≥10% body weight loss at 12 months; mean -9.8% weight loss in adults.
- PWS Phase 2 six-month results announced June 13 (separate press release).
- No new financial guidance, revenue, or EPS figures were disclosed.
Financial Impact
No financial figures disclosed; data supports continued commercial adoption and pipeline expansion for setmelanotide and bivamelagon.
Risk Factors
- Competition from other MC4R agonists and GLP-1 therapies for broader obesity.
- Regulatory setbacks for bivamelagon or PWS indication.
- Commercial execution risk for setmelanotide in acquired HO and BBS.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3312120 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 17d ago | 144 | $96.77 $99.27 | ▼ −2.58% | ▼ −0.47% | $93.68 (+3.19%) |
Aug 17, 2026 6w ago | Insider Cluster | $115.25 $113.35 | ▲ +1.65% | ▲ +1.45% | $93.68 (+18.72%) |
Aug 17, 2026 6w ago | Insider Cluster | $115.25 $113.35 | ▼ −1.65% | ▼ −1.45% | $93.68 (−18.72%) |
Aug 4, 2026 8w ago | 8-K | $105.78 $112.85 | ▲ +6.68% | ▲ +6.78% | $93.68 (−11.44%) |
Aug 4, 2026 8w ago | Press Release | $105.78 $112.85 | ▲ +6.68% | ▲ +6.78% | $93.68 (−11.44%) |
Jul 8, 2026 12w ago | Press Release | $115.48 $106.09 | ▼ −8.13% | ▼ −8.00% | $93.68 (−18.88%) |
Jun 22, 2026 14w ago | 144 | $106.19 $110.04 | ▲ +3.63% | ▲ +2.61% | $93.68 (−11.78%) |
Jun 15, 2026 15w ago | 8-K | $89.72 $106.19 | ▲ +18.36% | ▲ +20.59% | $93.68 (+4.41%) |
Jun 15, 2026 15w ago | Press Release | $89.72 $106.19 | ▲ +18.36% | ▲ +20.59% | $93.68 (+4.41%) |
Jun 13, 2026 15w ago | Press Release | $89.70 $101.39 | ▲ +13.03% | ▲ +14.42% | $93.68 (+4.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access